{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:58:34Z","timestamp":1784926714215,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,7,17]],"date-time":"2008-07-17T00:00:00Z","timestamp":1216252800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1007\/s10928-008-9093-5","type":"journal-article","created":{"date-parts":[[2008,7,16]],"date-time":"2008-07-16T11:25:19Z","timestamp":1216207519000},"page":"379-399","source":"Crossref","is-referenced-by-count":14,"title":["Population PK\u2013PD model for Fc-osteoprotegerin in healthy postmenopausal women"],"prefix":"10.1007","volume":"35","author":[{"given":"Matthew L.","family":"Zierhut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc R.","family":"Gastonguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vicini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirow J.","family":"Bekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip T.","family":"Leese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,7,17]]},"reference":[{"key":"9093_CR1","first-page":"657","volume":"81","author":"K Akesson","year":"2003","unstructured":"Akesson K (2003) New approaches to pharmacological treatment of osteoporosis. Bull World Health Organ 81: 657\u2013664","journal-title":"Bull World Health Organ"},{"key":"9093_CR2","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1001\/archinte.163.18.2237","volume":"163","author":"MP Ettinger","year":"2003","unstructured":"Ettinger MP (2003) Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Arch Intern Med 163: 2237\u20132246. doi: 10.1001\/archinte.163.18.2237","journal-title":"Arch Intern Med"},{"issue":"Suppl 2","key":"9093_CR3","first-page":"11","volume":"6","author":"R Sitruk-Ware","year":"2003","unstructured":"Sitruk-Ware R (2003) Alternatives for optimal hormone replacement therapy. Climacteric 6(Suppl 2): 11\u201316","journal-title":"Climacteric"},{"key":"9093_CR4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1196\/annals.1290.040","volume":"997","author":"MW Draper","year":"2003","unstructured":"Draper MW (2003) The role of selective estrogen receptor modulators (SERMs) in postmenopausal health. Ann N Y Acad Sci 997: 373\u2013377. doi: 10.1196\/annals.1290.040","journal-title":"Ann N Y Acad Sci"},{"key":"9093_CR5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0749-0690(02)00074-5","volume":"19","author":"MR Rubin","year":"2003","unstructured":"Rubin MR, Bilezikian JP (2003) The anabolic effects of parathyroid hormone therapy. Clin Geriatr Med 19: 415\u2013432. doi: 10.1016\/S0749-0690(02)00074-5","journal-title":"Clin Geriatr Med"},{"key":"9093_CR6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423: 337\u2013342. doi: 10.1038\/nature01658","journal-title":"Nature"},{"key":"9093_CR7","first-page":"268","volume":"4","author":"LC Hofbauer","year":"2004","unstructured":"Hofbauer LC, Kuhne CA, Viereck V (2004) The OPG\/RANKL\/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 4: 268\u2013275","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"9093_CR8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1359\/jbmr.2001.16.2.348","volume":"16","author":"PJ Bekker","year":"2001","unstructured":"Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR (2001) The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16: 348\u2013360. doi: 10.1359\/jbmr.2001.16.2.348","journal-title":"J Bone Miner Res"},{"key":"9093_CR9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/0091270003252480","volume":"43","author":"WA Colburn","year":"2003","unstructured":"Colburn WA (2003) Biomarkers in drug discovery and development: from target identification through drug marketing. J Clin Pharmacol 43: 329\u2013341. doi: 10.1177\/0091270003252480","journal-title":"J Clin Pharmacol"},{"key":"9093_CR10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5414\/CPP40281","volume":"40","author":"JV Gobburu","year":"2002","unstructured":"Gobburu JV, Sekar VJ (2002) Application of modeling and simulation to integrate clinical pharmacology knowledge across a new drug application. Int J Clin Pharmacol Ther 40: 281\u2013288","journal-title":"Int J Clin Pharmacol Ther"},{"key":"9093_CR11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/jps.1167","volume":"91","author":"B Meibohm","year":"2002","unstructured":"Meibohm B, Derendorf H (2002) Pharmacokinetic\/pharmacodynamic studies in drug product development. J Pharm Sci 91: 18\u201331. doi: 10.1002\/jps.1167","journal-title":"J Pharm Sci"},{"key":"9093_CR12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1146\/annurev.pharmtox.40.1.209","volume":"40","author":"NH Holford","year":"2000","unstructured":"Holford NH, Kimko HC, Monteleone JP, Peck CC (2000) Simulation of clinical trials. Annu Rev Pharmacol Toxicol 40: 209\u2013234. doi: 10.1146\/annurev.pharmtox.40.1.209","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"9093_CR13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1023\/A:1023525513696","volume":"21","author":"KS Blesch","year":"2003","unstructured":"Blesch KS, Gieschke R, Tsukamoto Y, Reigner BG, Burger HU, Steimer JL (2003) Clinical pharmacokinetic\/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience. Invest New Drugs 21: 195\u2013223. doi: 10.1023\/A:1023525513696","journal-title":"Invest New Drugs"},{"key":"9093_CR14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1023\/A:1013667718695","volume":"19","author":"R Gomeni","year":"2002","unstructured":"Gomeni R, Dangeli C, Bye A (2002) In silico prediction of optimal in vivo delivery properties using convolution-based model and clinical trial simulation. Pharm Res 19: 99\u2013103. doi: 10.1023\/A:1013667718695","journal-title":"Pharm Res"},{"key":"9093_CR15","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1023\/A:1010943430471","volume":"18","author":"I Nestorov","year":"2001","unstructured":"Nestorov I, Graham G, Duffull S, Aarons L, Fuseau E, Coates P (2001) Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptan. Pharm Res 18: 1210\u20131219. doi: 10.1023\/A:1010943430471","journal-title":"Pharm Res"},{"key":"9093_CR16","unstructured":"Research, USDoHaH, Administration, FaD, (CDER), CfDEaR & (CBER), CfBEaR guidance for industry population pharmacokinetics (1999)"},{"key":"9093_CR17","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2125.2004.02224.x","volume":"58","author":"G Pillai","year":"2004","unstructured":"Pillai G, Gieschke R, Goggin T, Jacqmin P, Schimmer RC, Steimer JL (2004) A semimechanistic and mechanistic population PK\u2013PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br J Clin Pharmacol 58: 618\u2013631. doi: 10.1111\/j.1365-2125.2004.02224.x","journal-title":"Br J Clin Pharmacol"},{"key":"9093_CR18","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00228-001-0411-8","volume":"57","author":"S Cremers","year":"2002","unstructured":"Cremers S, Sparidans R, den HJ, Hamdy N, Vermeij P, Papapoulos S (2002) A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. Eur J Clin Pharmacol 57: 883\u2013890. doi: 10.1007\/s00228-001-0411-8","journal-title":"Eur J Clin Pharmacol"},{"key":"9093_CR19","unstructured":"Beal SL, Sheiner LB (1992) NONMEM User Guide. In: NONMEM Project Group. University of California San Francisco, San Francisco"},{"key":"9093_CR20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3109\/03602538409015066","volume":"15","author":"JL Steimer","year":"1984","unstructured":"Steimer JL, Mallet A, Golmard JL, Boisvieux JF (1984) Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev 15: 265\u2013292. doi: 10.3109\/03602538409015066","journal-title":"Drug Metab Rev"},{"key":"9093_CR21","doi-asserted-by":"crossref","unstructured":"Carroll RJ, Ruppert D (1988) Transformation and weighting in regression. CRC Press","DOI":"10.1007\/978-1-4899-2873-3"},{"key":"9093_CR22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO (1999) Xpose\u2013an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58: 51\u201364. doi: 10.1016\/S0169-2607(98)00067-4","journal-title":"Comput Methods Programs Biomed"},{"key":"9093_CR23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1011555016423","volume":"28","author":"Y Yano","year":"2001","unstructured":"Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic\/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28: 171\u2013192. doi: 10.1023\/A:1011555016423","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9093_CR24","volume-title":"Modelling Economic Series","author":"EE Leamer","year":"1990","unstructured":"Leamer EE (1990) Sensitivity analysis would help. In: Granger CWJ (eds) Modelling Economic Series. Clarendon Press, Oxford"},{"key":"9093_CR25","first-page":"577","volume":"27","author":"IA Nestorov","year":"1999","unstructured":"Nestorov IA (1999) Sensitivity analysis of pharmacokinetic and pharmacodynamic systems: I. A structural approach to sensitivity analysis of physiologically based pharmacokinetic models. J Pharmacokinet Biopharm 27: 577\u2013596. doi: 10.1023\/A:1020926525495","journal-title":"A structural approach to sensitivity analysis of physiologically based pharmacokinetic models. J Pharmacokinet Biopharm"},{"key":"9093_CR26","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1023\/A:1012065130597","volume":"14","author":"V Piotrovskij","year":"1997","unstructured":"Piotrovskij V, Van Peer A (1997) A model with separate hepato-portal compartment (\u201cfirst-pass\u201d model): fitting to plasma concentration-time profiles in humans. Pharm Res 14: 230\u2013237. doi: 10.1023\/A:1012065130597","journal-title":"Pharm Res"},{"key":"9093_CR27","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","volume":"18","author":"R Eastell","year":"2003","unstructured":"Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18: 1051\u20131056. doi: 10.1359\/jbmr.2003.18.6.1051","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-008-9093-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-008-9093-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-008-9093-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T04:56:41Z","timestamp":1559451401000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-008-9093-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,17]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["9093"],"URL":"https:\/\/doi.org\/10.1007\/s10928-008-9093-5","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,17]]}}}